Ocular Melanoma clinical trials at UCSD
4 research studies open to eligible people
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
open to eligible people ages 18 years and up
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
La Jolla, California and other locations
Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
open to eligible people ages 18 years and up
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
La Jolla, California and other locations
RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
open to all eligible people
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
La Jolla, California and other locations
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
open to eligible people ages 18 years and up
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
La Jolla, California and other locations
Last updated: